BRPI0512944A - agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 - Google Patents
agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1Info
- Publication number
- BRPI0512944A BRPI0512944A BRPI0512944-3A BRPI0512944A BRPI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- hmgb1
- therapeutic agents
- related conditions
- nucleic acid
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000055207 HMGB1 Human genes 0.000 abstract 1
- 108700010013 HMGB1 Proteins 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58467804P | 2004-07-02 | 2004-07-02 | |
| US64658605P | 2005-01-26 | 2005-01-26 | |
| PCT/EP2005/007198 WO2006002971A2 (en) | 2004-07-02 | 2005-07-04 | Nucleic acids for the treatment of hmgb1-related pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512944A true BRPI0512944A (pt) | 2008-04-15 |
Family
ID=35106975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512944-3A BRPI0512944A (pt) | 2004-07-02 | 2005-07-04 | agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080305073A1 (enExample) |
| EP (1) | EP1768677B1 (enExample) |
| JP (1) | JP2008504335A (enExample) |
| AT (1) | ATE399014T1 (enExample) |
| AU (1) | AU2005259381A1 (enExample) |
| BR (1) | BRPI0512944A (enExample) |
| CA (1) | CA2572519A1 (enExample) |
| DE (1) | DE602005007746D1 (enExample) |
| DK (1) | DK1768677T3 (enExample) |
| ES (1) | ES2306195T3 (enExample) |
| IL (1) | IL179828A0 (enExample) |
| PL (1) | PL1768677T3 (enExample) |
| PT (1) | PT1768677E (enExample) |
| WO (1) | WO2006002971A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007001559A (es) | 2004-08-03 | 2007-04-10 | Transtech Pharma Inc | Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso. |
| US20100172909A1 (en) * | 2005-10-24 | 2010-07-08 | Masahiro Nishibori | Cerebral edema suppressant |
| CN101410411A (zh) * | 2006-02-09 | 2009-04-15 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| JP3882090B1 (ja) * | 2006-05-19 | 2007-02-14 | 国立大学法人 岡山大学 | 脳血管攣縮抑制剤 |
| KR20090087483A (ko) * | 2006-11-17 | 2009-08-17 | 클리니컬 진 네트웍스 아베 | 유전자 ｇｙｐｃ, ａｇｐａｔ3, ａｇｌ, ｐｖｒｌ2, ｈｍｇｂ3, ｈｓｄｌ2 및/또는 ｌｄｂ2를 포함하는 스크리닝 및 치료방법 |
| CN101589309A (zh) * | 2006-11-17 | 2009-11-25 | 临床基因网络公司 | 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法 |
| WO2009140676A2 (en) * | 2008-05-16 | 2009-11-19 | Immune Disease Institute, Inc. | Compositions and methods for inhibition of retroviruses |
| US8710021B2 (en) | 2008-06-11 | 2014-04-29 | Bionucleon S.R.L. | Inhibition of HRP-3 using modified oligonucleotides |
| JP5710482B2 (ja) | 2008-09-11 | 2015-04-30 | アンスティテュ・パストゥール | Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害 |
| US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
| BRPI0923583A2 (pt) | 2008-12-22 | 2018-10-09 | Creabilis S A | síntese de conjugados de polímeros de compostos de indocarbzol. |
| EP2421892A1 (en) | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| GB0911569D0 (en) * | 2009-07-03 | 2009-08-12 | Ulive Entpr Ltd | Method for the detection of organ or tissue injury |
| JP5467313B2 (ja) * | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
| US8975019B2 (en) * | 2009-10-19 | 2015-03-10 | University Of Massachusetts | Deducing exon connectivity by RNA-templated DNA ligation/sequencing |
| JP5686814B2 (ja) | 2010-09-17 | 2015-03-18 | 独立行政法人科学技術振興機構 | Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法 |
| WO2013116590A1 (en) * | 2012-02-01 | 2013-08-08 | George Miller | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
| JP6624542B2 (ja) * | 2015-02-05 | 2019-12-25 | 国立大学法人広島大学 | ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置 |
| WO2018175340A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| WO2018175315A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates of staurosporine derivatives having reduced exposure |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| WO2018175301A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugate of montesanib with reduced exposure |
| WO2018208369A1 (en) | 2017-05-10 | 2018-11-15 | Sienna Biopharmaceuticals, Inc. | Uses of polymer conjugates of indolocarbazole compounds with reduced exposure |
| CN111304202B (zh) * | 2020-02-26 | 2023-03-28 | 西安交通大学 | 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用 |
| CN114957440A (zh) * | 2022-05-26 | 2022-08-30 | 江苏大学 | 一种重组HMGB1 A Box蛋白及其获取方法与应用 |
| JP2025521607A (ja) * | 2022-06-23 | 2025-07-10 | ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン | アルツハイマー病を含むａｐｏｅ４－関連タウオパチーの治療のためのｈｍｇｂ１阻害剤 |
| CN114807150B (zh) * | 2022-06-28 | 2022-10-14 | 中国科学院基础医学与肿瘤研究所(筹) | 靶向和拮抗hmgb1分子的核酸适体 |
| WO2024020320A2 (en) | 2022-07-19 | 2024-01-25 | Rampart Bioscience, Inc. | Non-immunogenic circular, non-viral dna vectors |
| CN115774004B (zh) * | 2022-08-19 | 2024-07-05 | 四川大学华西医院 | 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009158A1 (en) * | 1992-10-14 | 1994-04-28 | University Research Corporation | Method for selecting nucleic acids on the basis of structure |
| ITMI20010562A1 (it) * | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| NZ540067A (en) * | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
-
2005
- 2005-07-04 PT PT05773148T patent/PT1768677E/pt unknown
- 2005-07-04 WO PCT/EP2005/007198 patent/WO2006002971A2/en not_active Ceased
- 2005-07-04 CA CA002572519A patent/CA2572519A1/en not_active Abandoned
- 2005-07-04 ES ES05773148T patent/ES2306195T3/es not_active Expired - Lifetime
- 2005-07-04 DE DE602005007746T patent/DE602005007746D1/de not_active Revoked
- 2005-07-04 AU AU2005259381A patent/AU2005259381A1/en not_active Abandoned
- 2005-07-04 BR BRPI0512944-3A patent/BRPI0512944A/pt not_active IP Right Cessation
- 2005-07-04 EP EP05773148A patent/EP1768677B1/en not_active Revoked
- 2005-07-04 US US11/631,328 patent/US20080305073A1/en not_active Abandoned
- 2005-07-04 DK DK05773148T patent/DK1768677T3/da active
- 2005-07-04 AT AT05773148T patent/ATE399014T1/de not_active IP Right Cessation
- 2005-07-04 PL PL05773148T patent/PL1768677T3/pl unknown
- 2005-07-04 JP JP2007518555A patent/JP2008504335A/ja active Pending
-
2006
- 2006-12-04 IL IL179828A patent/IL179828A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006002971A3 (en) | 2006-04-20 |
| CA2572519A1 (en) | 2006-01-12 |
| JP2008504335A (ja) | 2008-02-14 |
| AU2005259381A1 (en) | 2006-01-12 |
| ES2306195T3 (es) | 2008-11-01 |
| EP1768677B1 (en) | 2008-06-25 |
| DE602005007746D1 (de) | 2008-08-07 |
| IL179828A0 (en) | 2008-03-20 |
| PL1768677T3 (pl) | 2009-01-30 |
| EP1768677A2 (en) | 2007-04-04 |
| DK1768677T3 (da) | 2008-10-20 |
| WO2006002971A2 (en) | 2006-01-12 |
| ATE399014T1 (de) | 2008-07-15 |
| PT1768677E (pt) | 2008-10-06 |
| US20080305073A1 (en) | 2008-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512944A (pt) | agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| DE602006019838D1 (de) | Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten | |
| ATE499088T1 (de) | Glp-1-fc fusionsprotein-formulierung | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| DE502006004066D1 (de) | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen | |
| EA200702358A1 (ru) | Комбинация ингибитора pde4 и производного тетрагидробиоптерина | |
| CY1114965T1 (el) | Cpg ολιγονουκλεοτιδια χρησιμοποιουμενα για ενισχυση της δραστικοτητας στεροειδων σε εναν εξαρτημενο απο στεροειδη ασθενη | |
| EA201370208A1 (ru) | Формы рифаксимина и их применение | |
| EP1957413A4 (en) | Sewage treatment | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| EA201100297A1 (ru) | Биотесты на белок polyq | |
| BRPI0722054A2 (pt) | Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico. | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| ATE472998T1 (de) | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis | |
| ATE447551T1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| ECSP066559A (enExample) | ||
| ATE474574T1 (de) | Imidazoazephinonverbindungen | |
| EA200801244A1 (ru) | Применение sdf-1 для лечения и/или профилактики неврологических заболеваний | |
| EA200702336A1 (ru) | ПРИМЕНЕНИЕ 24-норУДХК | |
| EA201070496A1 (ru) | УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ | |
| EA201070494A1 (ru) | МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ | |
| NI201000067A (es) | Intermediarios de gsm. | |
| FR2905600B1 (fr) | Traitement des vertiges par l'acetyl-l-leucine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |